Connect with us

General Other

Trump denies scientific consensus that climate change is supercharging the West’s wildfires

mm

Published

on

Trump denies scientific consensus that climate change is supercharging the West's wildfires
U.S. President Trump participates in a briefing on wildfires in McClellan Park in McClellan Park, California

  • President Donald Trump denied that climate change played a factor in the record-setting wildfires ravaging the West Coast.

  • “It’ll start getting cooler,” Trump said on Monday during a briefing in California on the wildfires. “You just watch.”

  • “I wish science agreed with you,” California Natural Resources Secretary Wade Crowfoot responded.

  • The fires have burned more than 5 million acres and killed at least 26 people as of Monday. 

  • Visit Business Insider’s homepage for more stories.

President Donald Trump again shrugged off scientific consensus that climate change is a significant factor fueling the record-setting wildfires devastating several western states.

“It’ll start getting cooler, you just watch,” Trump said on Monday in California while being briefed on the ongoing wildfires by Gov. Gavin Newsom and other state leaders. 

“I wish science agreed with you,” Wade Crowfoot, the state’s natural resources secretary, pushed back.

Newsom and Crowfoot pointed to earlier comments Trump made that forest management is largely to blame for the unprecedented wildfires disrupting lives across parts of California, Oregon, and Washington state. More than 5 million acres have been burned, hundreds of thousands have evacuated their homes and at least 26 people have died as of Monday.

“We have not done justice on our forest management. I don’t think anyone disputes that,” Newsom acknowledged, but he added, “climate change is real and that is exacerbating this.” 

“We want to work with you to really recognize the changing climate and what it means to our forests,” Crowfoot told Trump. “That science is going to be key. If we ignore that science and sort of put our head in the sand and think it’s all about vegetation management, we’re not going to succeed together protecting Californians.”

“I don’t think science knows, actually,” Trump responded and quickly moved on to the next set of questions.

The scientific community agrees that changes in climate, such as higher temperatures, can lead to drier and warmer conditions that increase wildfire risk and extend its duration. California and other western states are experiencing record heat waves and years-long drought. Recent environmental research found that climate change is linked to the increasing fire risk in parts of California. 

Other factors, including land use and forest management, also contribute to the fires. 

The president has long dismissed the growing climate crisis and previously called the science a “hoax” perpetrated by the Chinese to hurt the US economy. As president, Trump has reversed or undermined every significant federal policy designed to reduce emissions that contribute to climate change.

Even after his daughter and top adviser Ivanka attempted to stop her father from abandoning the Paris Climate Accord, Trump withdrew from the landmark international agreement in 2017.

A New York Times report found the Trump administration had rolled back or gotten rid of at least 70 environmental regulations and 30 more such policy reversals were in progress as of mid-July. 

Meanwhile, Democratic presidential nominee Joe Biden blasted Trump as a “climate arsonist” during a campaign speech on Monday, warning four more years of Trump would mean worsening wildfires, hurricanes, and other climate-related natural disasters.

“If we have four more years of Trump’s climate denial, how many suburbs will be burned in wildfires?” Biden said, referencing Trump’s claims that Biden’s housing and law enforcement policies would “abolish” the suburbs. “How many suburban neighborhoods will have been flooded out? How many suburbs will have been blown away in superstorms?”

Read the original article on Business Insider

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

General Other

‘Miracle on the Hudson’ pilot Sully Sullenberger said he’ll only fly with airlines that block the middle seat during the pandemic

mm

Published

on

'Miracle on the Hudson' pilot Sully Sullenberger said he'll only fly with airlines that block the middle seat during the pandemic
Sully Sullenberger compares the approach to coronavirus risk mitigation to the rules and practices that govern commercial flight safety.

Airlines have been divided over whether blocking middle seats on airplanes during the coronavirus pandemic is worthwhile, and whether it really makes flying safer. 

Now, one of the most authoritative figures in aviation safety has weighed in — and he doesn’t want anyone sitting next to him. 

Captain Chesley Burnett “Sully” Sullenberger III, the pilot famous for landing a damaged plane on the Hudson River with no fatalities in 2009, said that he only plans to fly aboard airlines that block off middle seats during the pandemic.

Sullenberger revealed his preference in an interview with Eric Schmidt on the former Google CEO’s podcast, “Reimagine with Eric Schmidt.”

Sullenberger cited a study from MIT that found that leaving the middle seat empty roughly halves the risk of catching the novel coronavirus during a flight.

“And I’ll tell you, I’m going to fly on an airplane where the middle seats are kept empty, knowing that my chances of catching COVID are half that if middle seat were filled,” Sullenberger said.

Sullenberger compared the approach to coronavirus risk mitigation to the rules and practices that govern commercial flight safety.

“Air travel has become ultra safe, something I wouldn’t have thought possible 35 or 40 years ago,” he said. “Airline accidents now are very rare. But we must keep on making investments to keep it either that safe or getting safer investments in people, in systems, in technology. “

Sullenberger also faulted the federal government for not developing standardized practices to be employed nationwide during the pandemic.

“One of the biggest failure so far in terms of our air transportation system is that in this country we have never had a federal face covering mandate in spite of the fact that many have been calling for that,” Sullenberger said. “And that would have been one of the most effective things that we could do.”

“Instead, individual airlines are having to come up with their own policies and procedures,” he added. “And to try to encourage the flight attendants to be the cop on the beat and to enforce these requirements that are really very basic.”

The retired pilot also criticized the politicization of standard COVID-19 risk mitigation efforts.

“It really disturbs me greatly the extent to which for this whole episode, unlike any other crisis we’ve had in our nation’s history, these basic safety requirements have become so extremely politicized and an extension of an ongoing cultural war,” Sullenberger said. “And that has done and continues to do great harm.”

“We have acquired the data to know what works and what doesn’t, where the relative risks are and began to take effective steps to mitigate each part of the process,” he added. “You see, there’s not one silver bullet that will solve the whole problem. Instead, we must rely upon a whole panoply of individual actions that, in aggregate, can make us all safer.”

Schmidt also spoke with former Airbus CEO Tom Enders during the podcast episode. Enders similarly called for standardized regulations to help reduce the risk of COVID-19 on planes, as well as to reassure passengers.

“For the international air traffic to function seamlessly, as it did almost before COVID-19, it’s wildly important we have the same rules all over the place,” Enders said.

Enders also noted the irony of the fact that commercial aviation is, statistically, among the safest ways to travel, but has been so badly affected by the coronavirus pandemic.

“A simple statistic is that it’s more dangerous to drive to the airport than it is to fly from the airport,” Enders said. “So it seems totally unfair to the airline industry and the aircraft industry to have to deal with us. But nevertheless, here we are.”

The podcast episode was released on Tuesday. You can find the full 40-minute episode here.

Read the original article on Business Insider

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Fire TV Edition models are on sale at Amazon

mm

Published

on

Early Prime Day sale: Save up to 36 percent on Fire TV Edition models! (Photo: Amazon)

Yahoo Life is committed to finding you the best products at the best prices. We may receive a share from purchases made via links on this page. Pricing and availability are subject to change.

Early Prime Day sale: Save up to 36 percent on Fire TV Edition models! (Photo: Amazon)

Why wait until Amazon Prime Day? You can save right now with these Prime exclusive TV deals.

Amazon just announced the dates for its annual mega-shopping event—October 13 and 14, mark your calendars!—but the retail giant also dropped new early Prime Day deals to tide you over.

There are massive discounts on select Fire TV Edition TVs in sizes big and small. Here’s your chance to save up to 36 percent with prices starting at just $180.

All of the models below have Fire TV video streaming already built-in, so you can start watching popular TV shows like Stranger Things, The Crown, Tom Clancy’s Jack Ryan, The Marvelous Mrs. Maisel, The Mandalorian and much more without a cable subscription.

Take note: These Fire TV Edition deals are for Prime members only. Not a member? Sign up for a free 30-day trial to take advantage of the low prices. Plus, get free two-day shipping with Amazon Prime.

Shop the pre-Prime Day TV sales below:

Save $100 on this Toshiba 43-inch Smart HD TV—Fire TV Edition. (Photo: Amazon)

Amazon has the Toshiba 43-inch Smart HD TV—Fire TV Edition on sale for $180, down from $280, for Prime members only. That’s a $100 savings and the all-time lowest price we’ve ever seen on this model. With a Full HD resolution of 1080p, this TV is the perfect size for a small space. And it lets you stream movies and shows from Netflix, SlingTV, Hulu, Amazon Prime Video, Acorn TV, BritBox and much more. This model is so popular that it has earned an impressive five-star rating from more than 900 reviewers.

“This is the perfect TV and perfect to use with Fire Stick. It all works together. Easy to set up. Clear picture with excellent quality,” shared a satisfied shopper. “The remote works with the Fire Stick so you don’t need two remotes. I am so happy and in love with this TV.”

Save $100 on this Insignia 50-inch Smart 4K UHD—Fire TV Edition. (Photo: Amazon)

Step up to 4K with Amazon’s No. 1 best-seller in LED and LCD TVs: The Insignia 50-inch Smart 4K UHD—Fire TV Edition is on sale for $250, or $100 off. That’s the lowest price we’ve ever seen for this 4K model, which is a considerable upgrade from the 43-inch HD TV model listed above. The TV has a brilliant 4K resolution at 2160p; it comes with Fire TV built-in and is ready to stream popular video apps including Netflix, Crackle, Prime Video, Disney+, CNN, HBO Now and Starz. Over 850 shoppers love this TV so much that they gave it a flawless five-star rating.

“This TV is great for the size and quality of picture. I love that it has all the streaming sites already programmed. I’m not one to know a lot about all of this online stuff but it was very easy to start watching immediately without an antenna. I love it,” raved a five-star reviewer.

The reviews quoted above reflect the most recent versions at the time of publication.

Read More from Yahoo Life:

Follow us on Instagram, Facebook, Twitter and Pinterest for nonstop inspiration delivered fresh to your feed, every day.

Want daily pop culture news delivered to your inbox? Sign up here for Yahoo Entertainment & Life’s newsletter.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

‘Fast Money’ Traders Share Their Thoughts On AT&T, Coca-Cola

mm

Published

on

'Fast Money' Traders Share Their Thoughts On AT&T, Coca-Cola

TipRanks

Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%

When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is taking the latter view.Despite the volatility that has ruled the market over the last few weeks, Stoltzfus actually likes what he’s witnessing in both the market and the economy. In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets… We’ve taken out the froth that had come into the market in certain [mega cap] names. It may be a good opportunity to pick up some really good, high quality growth stories that are on sale right now,” Stoltzfus noted.Additionally, the strategist believes the S&P 500 could climb back to its September 2 high point, based on improving economic data. The approval of a COVID-19 vaccine as well as an election outcome that is “friendly to the domestic economy, business, job growth and the taxpayer” could also push the index higher.Turning Stoltzfus’ outlook into tangible recommendations, Oppenheimer analysts are pounding the table on two stocks, with these pros seeing over 100% upside potential in store. Running the tickers through TipRanks’ database, we wanted to find out exactly what makes them so compelling.Brickell Biotech (BBI)Focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases, Brickell Biotech wants to improve the lives of patients everywhere. Given the potential of the company’s lead candidate and its $0.82 share price, Oppenheimer thinks that now is the time to pull the trigger.Sofpironium bromide (SB), a prescription treatment for axillary hyperhidrosis (AH, or excessive underarm sweating), is entering U.S. Phase 3 trials. This program will consist of two identical six-week studies, and will evaluate its ability to improve the condition per the objective (gravimetric sweat production) and subjective (HDSM-Ax) co-primary endpoints. Each is expected to last 12 months, and the first will kick off next quarter.Roughly 10 million people in the U.S. suffer from AH, with this condition interfering with daily social and professional activities. Currently, only 2.3 million receive prescription treatment, and some resort to invasive or permanent interventions like Botox, MiraDry or surgery.Oppenheimer’s Leland Gershell argues that more conservative approaches could be used to meet these medical needs. He also believes the recent entry of Eli Lilly’s competing product, Qbrexza, represents a significant step forward. That said, there’s “room for improvement” with this anti-cholinergic approach.Looking at a U.S. Phase 2b trial, the highest dose of BBI’s SB gel (15%) demonstrated 46% greater sweat reduction per gravimetric analysis compared to the placebo, with significant reductions in a validated patient-reported outcome instrument seen at all doses. Based on the trial data, efficacy is over 50% better than Qbrexza per label, despite higher baseline severity. In addition, their safety profiles were relatively similar.It should be noted that BBI will market the drug to U.S. dermatologists through a specialty salesforce of 120 representatives. According to Gershell’s estimates, uptake by 110,000 patients per year (just 5% of the currently treated AH population) translates to $200 million in gross sales. The analyst adds that patent issuance could extend market exclusivity to 2040.Adding to the good news, on September 25, BBI announced that Kaken Pharmaceutical, its development partner, got the green light to manufacture SB in Japan for the treatment of AH. Japan is the first country to approve the candidate, with the launch expected later this year.To sum it all up, Gershell stated, “By virtue of its efficacy, tolerability, and antiperspirant-like application, we believe SB offers an attractive profile in a market that offers much room for improved solutions. We encourage risk-tolerant investors to build a position ahead of upcoming newsflow.”To this end, Gershell rates BBI an Outperform (i.e. Buy) along with a $5 price target. This target conveys the analyst’s confidence in BBI’s ability to surge 502% from current levels. (To watch Gershell’s track record, click here)Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. As a result, BBI gets a Moderate Buy consensus rating. The $5 average price target is identical to Gershell’s. (See BBI stock analysis on TipRanks)Aldeyra Therapeutics (ALDX)As for Oppenheimer’s other pick, Aldeyra Therapeutics works to bring new treatment options for immune-related diseases to market. Based on the solid progress of its pipeline, the firm has high hopes for this healthcare name.Representing Oppenheimer, analyst Justin Kim points out that he came away from a recent conversation with the CEO even more confident in ALDX’s long-term growth prospects. Pivotal studies on reactive aldehyde species (RASP) are slated for Q4 2020, evaluating the action of reproxalap, Aldeyra’s lead therapy designed to clamp down on overactive inflammation, on tear levels of RASP over a period ranging from 1-2 days to 28 days. “Based on Phase 2a results, we are confident in the ability to replicate results in Q4 2020,” Kim stated.Given the potential of dry eye disease (DED) in the near-term, the analyst expects significant investor focus to land on clinical trial execution (Phase 3 RASP studies and safety study), which would support a potential NDA filing by the end of 2021, in Kim’s opinion. “Despite some volatility in the shares, we see a solid setup emerging as the company initiates its Phase 3 RASP studies in dry eye disease (DED),” he said.Speaking to the potential of RASP as an accepted dry eye endpoint, ALDX has experienced “a watershed moment,” with it facilitating an expedited path to registration (from traditional sign endpoints) and greater likelihood of clinical trial success, based on reproxalap’s mechanism of action (MoA) as a RASP-trap, according to Kim.He added, “Moreover, agreement on RASP could have broader implications for a commercial launch in dry eye, a market that we believe will see segmentation as more therapies with targeted MoAs become incorporated into the armamentarium.”“We continue to be impressed by the progress in achieving a potential concurrent filing for dry eye and allergic conjunctivitis (AC), appreciating the importance of a differentiated dry eye agent with action also in AC. As the dry eye therapeutic landscape increases its options, we expect greater segmentation of the heterogeneous patient population potentially beginning with reproxalap’s positioning in ‘allergic dry eye’,” the analyst concluded. For the rest of 2020, focus is likely to stay on Phase 3 study designs (assay work/development), execution and the potential readout in DED, which could set the stage for a commercial launch in DED and AC in 2022.If that wasn’t enough, based on the broader pipeline of candidates targeting PVR, inflammatory conditions and COVID-19, Kim sees “a rich environment of catalysts for the shares over the coming 12-18 months.”It should come as no surprise, then, that Kim stayed with the bulls. To this end, he kept an Outperform rating and $15 price target on the stock. Investors could be pocketing a gain of 110%, should this target be met in the twelve months ahead. (To watch Kim’s track record, click here)What does the rest of the Street have to say? Only Buy ratings, 2 to be exact, have been issued in the last three months. So, the consensus rating is a Moderate Buy. In addition, the $23.50 average price target suggests 227% upside potential from current levels. (See ALDX stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

Trending